Related Experiment Video
Updated: Jul 2, 2026
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Impact of multiple gene mutations in determining the severity of cardiomyopathy and heart failure
Tatiana Tsoutsman1, Richard D Bagnall, Christopher Semsarian
1Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Insights
Familial hypertrophic cardiomyopathy (FHC) is a diverse heart condition. Multiple mutations in FHC genes lead to more severe disease, but mouse models offer insights for new therapies.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Familial hypertrophic cardiomyopathy (FHC) is a primary cardiac disorder with diverse genetic causes and clinical presentations.
- Clinical heterogeneity in FHC is influenced by the specific causative gene, mutation location, and environmental factors.
- Multiple mutations occur in approximately 5% of FHC cases, often resulting in a more severe phenotype.
Purpose of the Study:
- To explore the genetic basis and clinical impact of multiple mutations in familial hypertrophic cardiomyopathy.
- To investigate the utility of multiple-mutation mouse models in understanding FHC pathogenesis.
- To identify potential therapeutic targets for FHC and its complications.
Main Methods:
- Review of genetic databases and clinical case studies of FHC.
- Analysis of mutation data in key FHC-associated genes (MYH7, MYBPC3, TNNI2).
- Evaluation of existing multiple-mutation mouse models for FHC research.
Main Results:
- At least 13 causative genes and over 450 mutations have been identified in FHC.
- Multiple mutations, particularly in MYH7 and MYBPC3, are associated with earlier onset, greater hypertrophy, and increased sudden cardiac death risk.
- Multiple-mutation mouse models effectively replicate human FHC phenotypes.
Conclusions:
- Multiple mutations contribute significantly to the severity and heterogeneity of familial hypertrophic cardiomyopathy.
- Multiple-mutation mouse models are valuable tools for studying FHC mechanisms and developing therapeutic strategies.
- Further research using these models can lead to novel treatments and prevention methods for FHC, heart failure, and sudden death.
Abstract:
1. Familial hypertrophic cardiomyopathy (FHC) is a primary cardiac disorder characterized by myocardial hypertrophy that demonstrates substantial diversity in both genetic causes and clinical manifestations. 2. Clinical heterogeneity can be explained by the causative gene (at least 13 have been identified to date), the position of the amino acid residue affected by a mutation within the protein (over 450 mutations have been reported to date) and modifying genetic and environmental factors. 3. Multiple mutations are found in up to 5% of human FHC cases, who typically present with a more severe phenotype compared with single-mutation carriers (i.e. earlier onset of disease, greater left ventricular hypertrophy and a higher incidence of sudden cardiac death events). 4. Multiple mutations usually involve MYH7, MYBPC3 and, to a lesser extent, TNNI2, reflecting the higher contribution of mutations in these genes to FHC. 5. Multiple-mutation mouse models appear to mimic the human multiple-mutation phenotype and, thus, will help improve our understanding of disease pathogenesis. The models provide a tool for future studies of disease mechanisms and signalling pathways in FHC and its sequelae (i.e. heart failure and sudden death), thereby allowing identification of novel targets for potential therapies and disease prevention strategies.
Related Concept Videos
01:17Pathophysiology of Heart Failure
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:27Heart Failure I: Introduction
01:29Cardiomyopathy V: Interprofessional Care
01:25Cardiomyopathy I: Introduction and Classification
01:29Heart Failure II: Pathophysiology